Skip to main content

Lupin's generic Onfi gets FDA approval

1/2/2019
Lupin has received the Food and Drug Administration’s blessing for Clobazam oral suspension, 2.5 mg/mL.

The product is a generic version of Lundbeck’s Onfi oral suspension, 2.5 mg/mL.

It is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in patients 2 years of age or older.

Clobazam oral suspension, 2.5 mg/mL had a market value of approximately $260.2 million, according to IQVIA September 2018 data.
X
This ad will auto-close in 10 seconds